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Resumo:
Mulher de 69 anos admitida por hemiparésia esquerda sú-
bita tendo a tomografia computadorizada (TC) encefálica 
excluído lesões agudas. Internada com o diagnóstico de 
acidente vascular cerebral isquémico. O quadro neurológi-
co reverteu completamente em menos de 24 horas e o es-
tudo etiológico revelou-se normal. Apurou-se uma história 
concomitante de ingestão de 6 litros de água por dia nos 
últimos 2 anos e a prova de restrição hídrica seguida pela 
administração de desmopressina confirmaram diagnóstico 
de diabetes insípida central. A ressonância magnética (RM) 
encefálica foi normal. TC de corpo revelou espessamento 
da parede arterial sugestivo de vasculite de grandes e mé-
dios vasos, fibrose retroperitoneal, infiltração perinefrítica, 
espessamento pleural e pericárdico e densificação difusa 
do grande epíploon com o estudo por angio-RM revelando 
lesões oclusivas micro-arteriais. Biópsia laparoscópica do 
grande epíploon revelou células gigantes multinucleadas de 
Touton CD68+, CD1A-, patognomónicas de doença de Er-
dheim-Chester, uma histiocitose não-Langerhans rara.
Palavras-chave: Acidente Vascular Cerebral; Diabetes In-
sípida Neurogénica; Doença de Erdheim-Chester; Fibrose 
Retroperitoneal; Polidipsia
Abstract: 
A 69-year-old woman presented with sudden left hemipare-
sis. Computed tomography (CT) scan excluded acute brain 
injuries. Patient was admitted with acute ischemic stroke of 
right hemisphere. There was full recovery within 24 hours and 
etiologic studies were normal. There was a concomitant his-
tory of ingestion of 6 litres of water per day over the previous 
2 years. Water deprivation test followed by the administration 
of desmopressin confirmed central diabetes insipidus diag-
nosis. Brain magnetic resonance imaging (MRI) was normal. 
Full body CT scan showed arterial wall thickening suggestive 
of large and medium vessels vasculitis, retroperitoneal fibro-
sis, perinephric infiltration, pleural and pericardial thicke-
ning and diffuse densification of greater omentum. Angio-MRI 
showed occlusive micro-arterial injuries. Laparoscopic biop-
sy of greater omentum revealed multinucleated giant Touton 
CD68+, CD1A- cells. This finding is pathognomonic of Erdhei-
m-Chester Disease, a rare non-Langerhans histiocytosis.
Keywords: Diabetes Insipidus, Neurogenic; Erdheim-Chester 
Disease; Polydipsia; Retroperitoneal Fibrosis; Stroke 
Introduction
Erdheim-Chester disease (ECD) is a rare, non-Langerhans 
histiocytosis, first described in 1930, with 650-1000 cases 
reported worldwide,1,2 characterized by xanthomatous infil-
tration of tissues by CD68-positive, CD1a-negative foamy 
histiocytes.2 Since 2016 ECD is considered as a histiocyte 
neoplasm, which means it is a slow-growing blood cancer. 
Probably, it has its origin in Langerhans cells, bone marrow 
derived haematopoietic stem and progenitor cells, monocyte 
and dendritic cell precursors.3,4 The mean age of2 diagno-
sis is 56.1 years ± 14.7 with male predominance. It is a true 
multisystem disease as almost all tissues may be infiltrated.1 
The multi-organ involvement with important clinical manifes-
tations, major impact in life expectancy and quality makes 
ECD a diagnostic challenge.
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Case Report
A 69-year-old female with no known previous medical disor-
ders presented to the Emergency Department with sudden 
left hemiparesis.
Brain computer tomography (CT) had no acute pathologi-
cal findings and the patient was admitted to Internal Medicine 
ward with the clinical diagnosis of right hemisphere ischemic 
stroke. There was a total recovery within 24 hours.
Holter and Doppler ultrasound of neck vessels were nor-
mal; echocardiogram revealed pericardial thickening.
A thorough clinical history revealed large water consump-
tion, about 6 litres per day, over the past two years.
Blood chemistry revealed: hypernatremia (147 mmol/L), 
erythrocyte sedimentation rate 114 mm/1st hour, serum os-
molality 293 mOsm/Kg and urinary osmolality 144 mOsm/kg.
For confirmation of diabetes insipidus it was done a water 
deprivation test. After 7 hours of water deprivation, plasma 
osmolality roseto 303 mOsm/kg (criteria for stopping the test) 
and urinary osmolality to 190 mOsm/kg (Table 1).
Desmopressin was administered to test central diabetes 
insipidus. Four hours after administration of subcutaneous 
desmopressin (2 mcg), plasma osmolality dropped to 294 
mOsm/Kg, urine osmolality increased to 366 mOsm/kg and 
urinary volume was only 70 cm3 (Table 2).
Brain MRI revealed normal hypophysis dimensions, but 
semioval centre had bilateral hyperintensities (probable mi-
cro-arterial occlusive aetiology) and both middle cerebral ar-
teries had stenosis of M1 segment.
Because of arterial findings in brain MRI, it was requested a 
cervico-thoraco-abdomino-pelvic CT scan, which revealed pa-
rietal thickening of all major arteries, including carotid arteries 
(Fig. 1A), thoracic aorta (Fig. 1B), abdominal aorta (Fig. 1C) 
and superior mesenteric artery. It also revealed pulmonary pa-
renchyma band densifications and bilateral thickening of pleu-
ra. Pyelocaliceal system parietal thickening, perinephrium adi-
pose tissue densification and greater omentum retroperitoneal 
fibrosis and densification were additional findings.
Fluorodeoxyglucose (FDG) positron emission tomography 
confirmed CT scan findings as well as distal uptake of bone 
marrow in both femurs (Fig. 2).
Laparoscopic surgery was carried out revealing greater 
omentum multiple white implants which were biopsied finding 
giant multinucleated Touton CD68+, CD1a- cells (Fig. 3). 
Being these findings pathognomonic of Erdheim-Chester 
disease, the patient started treatment with pegylated inter-
feron alpha.
Discussion
In summary, this patient was a 69-year-old woman with a mul-
ti-organ disease. The brain had vascular involvement as seen 
in the brain MRI and central diabetes insipidus. She had arte-
rial involvement with parietal thickening of small, middle and 
large vessels. The lungs had band densification of parenchy-
ma and pleural thickening and the heart had also pericardial 
thickening. The kidneys had pyelocaliceal and perinephric 
adipose tissue densification. There was retroperitoneal fibro-
sis and densification of the greater omentum and the bones 
were also affected as seen by the alterations in bone marrow 
of both femurs.
The differential diagnosis included, at first, an autoimmune 
aetiology, specifically a vasculitis, which is classically divided 
into small, middle or large vessel. This patient presented pa-
rietal thickening of all arteries, but antineutrophil cytoplasmic 
antibodies were negative, as were anti-nuclear antibody, Waller 
Rose reaction, anti-Scl-70, anti-CCPe, anti-β2glicoprotein, anti-
-cardiolipin, lupus anticoagulant, anti-SSA and SSB, anti-dsD-
NA, anti-nucleosomes, anti-histones and anti-RNP/SM.
An infectious aetiology was also excluded as blood tests for 
human immunodeficiency virus (HIV), hepatitis B, hepatitis C, 
Epstein-Barr virus, parvovirus B19, herpes simplex I and II, 
VDRL and IGRA were all negative.
The next step was infiltrative diseases as sarcoidosis or 
histiocytosis. For sarcoidosis the angiotensin converting en-
zyme was negative and the biopsies of the greater omentum 
implants revealed infiltration of giant multinucleated Touton 
CD68+, CD1a- cells, which are pathognomic findings of Er-
dheim-Chester disease and excluded sarcoidosis.
ECD is a rare multi-systemic disease of unknown aetiology. 
Its most common clinical finding is bone pain, affecting 50% 
of patients, since only 4% ECD patients present without sym-
metric osteosclerosis of the femurs. However this manifesta-
tion is unspecific at the age this diagnosis is usually made 
(40-70 years old).
The frequency of central nervous system (CNS) involvement 
varies from 25% - 50%. Infiltration can occur throughout the 
neuroaxis and can be intra or extra-axial. Symptoms reflect 
compression of local structures or deterioration of cognitive 
functions and gait in the presence of diffuse disease. Diabe-
tes insipidus is present in 25% of patients.2,5 CNS involvement 
is a strong prognostic factor and an independent predictor of 
death in cases of ECD.1,6
As there were no acute ischemic findings in the brain MRI 
and the left hemiparesis had full recovery, we assumed the 
concomitant diagnosis of transient ischemic attack. The arte-
rial findings pointed to our final diagnosis.
Central diabetes insipidus was diagnosed by water depri-
vation test and desmopressin test. There were no hypotha-
lamic or pituitary changes on the brain MRI but with desmo-
pressin test positive, it does not exclude the diagnosis.
Perinephric fat infiltration, known as ´hairy kidney´ is pre-
sent in 68% of cases.
In 30% of patients, images suggestive of retroperitoneal fi-
brosis are present.
Cardiovascular involvement is usually asymptomatic and 
detected incidentally by CT scan. The most common finding 
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Table 1: Water deprivation test
Time (hours) Plasma Osmolality (mOsm/kg) Urinary Osmolality (mOsm/kg) Urinary Volume (cm3)
0 293 144 0
7 303 190 1100
Table 2: Desmopressin administration test








0 303 190 1100
4 294 366 70
is infiltration of thoracic and abdominal aorta and respective 
branches. Pericardial disease may be present in 40% - 45% 
of patients and can present as pericarditis, effusion or tam-
ponade.
Lung involvement is present in 50% of ECD patients, pre-
senting as interlobular septal thickening, ground-glass opa-
cities or centrilobular opacities. These findings are usually 
asymptomatic, but some patients may present with cough or 
dyspnoea.
Our patient presented with all these clinical findings and, 
according to the proposed ECD classification,2 the diagnosis 
is a symptomatic multisystem ECD.
There have been few studies and no randomized clinical 
trials about treatment of ECD. Several treatment options were 
tried, including anti-cytokine directed therapy (anakinra, in-
fliximab, tocilizumab), corticosteroids and radiotherapy.4,5,7-11 
Figure 1: Computer tomography. Thickening of carotid arteries (1A), thoracic aorta (1B) and abdominal aorta (1C)
However, since the therapeutic modality with the largest su-
pporting efficacy evidence is pegylated IFN-alpha, this was 
our choice.2,5
The recent finding that 57% - 75% of ECD patients carry 
BRAFV600E mutations made a way to other therapeutic op-
tions with serine/threonine kinase inhibitors, such as vemu-
rafenib, which has become the reference second-line treat-
ment. However, our patient did not present this mutation.1,12
Prognosis was unfavourable before treatment with inter-
feron, with only 43% of patients being alive 32 months after 
diagnosis.13 This approach, however, increased this propor-
tion to 82.8% at 5 years.1
In this age of mutation targeted pharmacology, the finding 
that other recurrent mutations of the MAPK and PIK3 pa-
thways (NRAS, PIK3CA) are present in ECD patients can lead 
to new drugs that might, considerably, improve prognosis.1  ■
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Figure 3: Biopsy of greater omentum, 10x40. Infiltration of 
giant multinucleated Touton CD68+
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